Oragenics Inc  

(Public, NYSEMKT:OGEN)   Watch this stock  
Find more results for OTC:ORNI
-0.02 (-1.80%)
Mar 5 - Close
NYSEMKT real-time data - Disclaimer
Currency in USD
Range 0.95 - 1.19
52 week 0.70 - 3.74
Open 1.09
Vol / Avg. 57,344.00/34,880.00
Mkt cap 36.78M
P/E     -
Div/yield     -
EPS -0.22
Shares 36.18M
Beta 1.36
Inst. own 41%

Key stats and ratios

Q3 (Sep '14) 2013
Net profit margin -512.18% -1556.70%
Operating margin -514.83% -1570.41%
EBITD margin - -1563.00%
Return on average assets -32.21% -117.64%
Return on average equity -34.24% -128.19%
Employees 9 -
CDP Score - -


Suite 125, 4902 Eisenhower Blvd
TAMPA, FL 33634
United States - Map
+1-813-2867900 (Phone)
+1-813-2867904 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Oragenics, Inc. is focused on the discovery, development and commercialization of a range of technologies associated with oral health, antibiotics and other general health benefits. The Company is developing and seeking partners or commercializing four products, including ProBiora3, LPT3-04, SMaRT Replacement Therapy and MU1140-S. The Company is focusing its efforts on growing its oral probiotic business both with its branded Evora products and through licensing and private label sales (with ProBiora3). Its SMaRT Replacement Therapy is designed to be a treatment applied to the teeth that has the potential to offer protection against dental caries, or tooth decay.

Officers and directors

Frederick W. Telling Ph.D. Independent Chairman of the Board
Age: 62
Bio & Compensation  - Reuters
Michael O'Keefe Sullivan CPA Interim Principal Executive Officer, Chief Financial Officer, Treasurer, Secretary
Age: 57
Bio & Compensation  - Reuters
Alan W. Dunton M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters
Christine L. Koski Independent Director
Age: 56
Bio & Compensation  - Reuters
Robert C. Koski Independent Director
Age: 55
Bio & Compensation  - Reuters
Charles L. Pope CPA Independent Director
Age: 62
Bio & Compensation  - Reuters